• Cash position of $95.1M, with additional $11.1M RDTI received
• Refocusing on high-priority programs like 64/67Cu-SAR-bisPSMA for prostate cancer
• Successful treatment of first participant in SECuRE trial Cohort Expansion Phase

Clarity Pharmaceuticals has reported its quarterly activities, with a cash position of $95.1 million and an additional $11.1 million received in April for the FY24 research and development tax incentive (RDTI), providing a combined funding of circa $106 million expected to support the company's operations through the second half of calendar 2026. Following a review of its portfolio, Clarity will prioritize the development of 64/67Cu-SAR-bisPSMA for diagnostic and therapeutic applications in prostate cancer, as well as 64Cu-SARTATE in neuroendocrine tumours and 64Cu-SAR-Bombesin in breast and prostate cancers. The company will also continue to progress its Discovery Program, including assets like SAR-bisFAP and SAR-trastuzumab. Clarity has successfully treated the first participant in the Cohort Expansion Phase (Phase II) of the SECuRE trial with 67Cu-SAR-bisPSMA, following the successful completion of the Dose Escalation Phase. The company has also presented data on its diagnostic portfolio using 64Cu-SAR-bisPSMA at various world-leading conferences, demonstrating its potential to identify more lesions and earlier than currently approved PSMA PET agents. Clarity has also secured three US FDA Fast Track Designations for its SAR-bisPSMA agent, further strengthening its position in the PSMA-targeted diagnostic and therapeutic markets. The company has also signed new supply agreements for copper-64 in the US and Australia to ensure seamless, abundant production of this diagnostic isotope as it progresses its clinical trials and approaches commercialization.

Clarity expects the combined funding of circa $106 million to provide cash runway through to the second half of calendar 2026.